PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Vertex Opts for Avalon to Progress VX-944
From issue 58 of the PharmaDeals Review (2005-04-01)
Vertex has partnered its oncology agent VX-944 in a deal worth up to US$73 M. While Vertex's choice of the relatively small company Avalon as its most recent licensing partner is suprising in some respects, Avalon's technology and cancer focus are a good match for VX-944, and Vertex clearly believes it has a committed partner to progress the compound quickly to proof-of-concept.
Available as PDF
(Subscribers only)
Product Sale and Purchase Agreements
From issue 58 of the PharmaDeals Review (2005-04-01)
This article is adapted from PharmaVentures' recent report Pharmaceutical Deal Structures: The Essential Manual for Deal Makers. It examines some of the reasons for the sale and purchase of both single products and product portfolios, and discusses some of their characteristics and some of the key issues involved.
Available as PDF
(Subscribers only)
Therapy Focus: Acne
From issue 58 of the PharmaDeals Review (2005-04-01)
As many as 85% of people will at some point suffer from acne. However, the severity of the condition varies enormously, and a vast range of therapies and treatments are therefore being developed and marketed. This feature investigates the major acne-related deals of recent years, and their impact on the acne therapy area.
Available as PDF
(Subscribers only)
Shire and New River: Buying up the Competition
From issue 57 of the PharmaDeals Review (2005-03-01)
By acquiring the global rights to NRP104, New River Pharmaceuticals' Phase III ADHD treatment, Shire Pharmaceuticals has effectively licensed a successor to its market-leading ADHD drug, Adderall XR™ (extended-release mixed amphetamine salts). However, some analysts have expressed concern that Shire is not looking to diversify away from this therapy area.
Available as PDF
(Subscribers only)
Sepracor and ACADIA Forge CNS Alliance
From issue 57 of the PharmaDeals Review (2005-03-01)
Sepracor's partnership with ACADIA Pharmaceuticals, potentially worth US$95 M, has been forged to develop new drug candidates against CNS disorders, including sleep-related indications and schizophrenia. The collaboration will also determine whether certain ACADIA CNS projects could be advanced into clinical development.
Last Issue PDF
RSS